Welcome to LookChem.com Sign In|Join Free

Hubei Vanz Pharm Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
5th
years
Home>>Products>>cas 790299-79-5 99 % Masitinib powder

Product Certification&
Enterprise Certification

More Detail

Hubei Vanz Pharm Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Ms.Chelsea gao

Tel: 86-27-84492310

Ms.Bella Li

Tel: 008618986076206

Ms.Chelsea Gao

Tel: +86 27 84492310

Ms.Wendy

Tel: WhatsApp +8615927784577

Ms.Mirriam

Tel: +8618071739296

Mobile:

Tel: 86-27-84492310

Fax: 86-27-84402310

URL: http://www.vanzpharm.com/en/index.html

Province/state: Hubei

City: JIAYU

Street: FANHU INDUSTRY PARK

MaxCard:


    x
  • Ms.Bella Li
  • Ms.Chelsea Gao
Contact Suppliers

cas 790299-79-5 99 % Masitinib powder

CAS NO.790299-79-5

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,MoneyGram
Contact Supplier

Product Details

Keywords

  • Masitinib
  • Masitinib powder
  • 99% Masitinib

Quick Details

  • ProName: cas 790299-79-5 99 % Masitinib powde...
  • CasNo: 790299-79-5
  • Molecular Formula: C28H30N6OS
  • Appearance: white
  • Application: Masitinib may affect the survival peri...
  • DeliveryTime: 7-10 days
  • PackAge: drum
  • Port: Shanghai/Wuhan
  • ProductionCapacity: 1000 Kilogram/Month
  • Purity: 99
  • Storage: room
  • LimitNum: 1 Kilogram

Superiority

cas  790299-79-5  99 % Masitinib powder

Product Name:    Masitinib
CAS:    790299-79-5
MF:    C28H30N6OS
MW:    498.64
EINECS:    226-164-5

 

Details

cas  790299-79-5  99 % Masitinib powder

Product Name:    Masitinib
CAS:    790299-79-5
MF:    C28H30N6OS
MW:    498.64
EINECS:    226-164-5 

Masitinib is studied and developed by the AB Science, a platelet-derived growth factor alpha/beta receptor tyrosine kinase inhibitor for the treatment of multiple myeloma, gastrointestinal stromal tumors and prostate cancer.

Masitinib is a novel kind of oral administrated tyrosine kinase inhibitors that could be targeted to immunizing important cellular mast cells and macrophages by inhibiting a certain amount of kinase. Based on its unique mechanism of action, masitinib can be developed for application in tumors, inflammatory diseases and certain central nervous system diseases.
In the oncology, due to its immunotherapy effect, Masitinib may affect the survival period of cancer patients (single administration or in combination with chemotherapy). By acting on mast cells and microglia, and further inhibiting the activation of the inflammatory process, Masitinib is effective against certain inflammatory, central nervous system disorders as well as symptoms associated with degeneration of these diseases.